Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
Abstract. The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not on
Abstract. The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not on
Breast cancer cases are increasing among younger women, which means it now makes sense to start regular screening younger, a federal task force says.
Blood | 143 | 18 | May 2024
The average total compensation for CEOs of the major health insurance companies increased 5.7% to $20.6 million last year, according to regulatory filings.
The world’s most influential people in health have made fresh discoveries, dreamed up novel treatments, and pioneered global victories over disease.
Location Henry B González Convention Center 900 E Market Street San Antonio, Texas Phone: (210) 207-8500 Program Schedule — Central Time 7:30 AM – 8:00…
Background Fee-for-service is a common payment model for remunerating general practitioners (GPs) in OECD countries. In Norway, GPs earn two-thirds of their income through fee-for-service,…
New mouse model allows for side-by-side comparison of antitumor activity and side effects of immunotherapeutics targeting the same epitope.Immunotherapies
Myeloma Paper of the Day, May 1st, suggested by Robert Orlowski / anti-cancer activity, cancer, MD Anderson Cancer Center, MDM2 inhibitors, Myeloma, Myeloma
Join the Harold C. Simmons Comprehensive Cancer Center on May 3 – 4, 2024, for the Wendy & Emery Reves International Breast Cancer Symposium. Register…
It may have been a given that Nick Norwitz would become a doctor – he is the child of physicians. “It was in some ways…